ESPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Esperion Therapeutics Inc (ESPR) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock exhibits mixed technical indicators, neutral trading sentiment, and no significant positive catalysts. While the company's revenue has grown significantly YoY, the negative net income and declining gross margin are concerning. The lack of recent news, congress trading data, and analyst updates further limits confidence in the stock's immediate potential.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 44.125, suggesting no clear trend. Moving averages are converging, showing indecision in price movement. The stock is trading below the pivot level of 3.454, with support at 3.288 and resistance at 3.621.
Revenue increased by 69.10% YoY in Q3 2025, showing strong top-line growth.
Net income remains negative at -31.33M, and gross margin dropped significantly by -20.76% YoY. No recent news, congress trading data, or analyst updates to support a bullish case.
In Q3 2025, revenue increased to $87.31M (up 69.10% YoY), net income improved slightly to -$31.33M (up 6.13% YoY), and EPS rose to -0.16 (up 6.67% YoY). However, gross margin declined to 52.71% (down -20.76% YoY), indicating cost pressures.
No recent analyst rating or price target changes available.
